XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 82 filers reported holding XENON PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,114,775 | -9.4% | 266,826 | +2.1% | 0.00% | – |
| Q2 2023 | $10,062,091 | +12.7% | 261,353 | +4.8% | 0.00% | – |
| Q1 2023 | $8,924,380 | +17.8% | 249,354 | +29.8% | 0.00% | – |
| Q4 2022 | $7,573,557 | +13.3% | 192,076 | +3.7% | 0.00% | – |
| Q3 2022 | $6,686,000 | +19.6% | 185,192 | +0.7% | 0.00% | – |
| Q2 2022 | $5,592,000 | +11.9% | 183,845 | +12.5% | 0.00% | – |
| Q1 2022 | $4,997,000 | +4.3% | 163,468 | +6.6% | 0.00% | – |
| Q4 2021 | $4,792,000 | +192.6% | 153,366 | +43.1% | 0.00% | – |
| Q3 2021 | $1,638,000 | -15.0% | 107,192 | +3.6% | 0.00% | – |
| Q2 2021 | $1,926,000 | +0.7% | 103,436 | -3.1% | 0.00% | – |
| Q1 2021 | $1,912,000 | +27.5% | 106,795 | +9.5% | 0.00% | – |
| Q4 2020 | $1,500,000 | +42.7% | 97,563 | +2.8% | 0.00% | – |
| Q3 2020 | $1,051,000 | -11.6% | 94,893 | +0.2% | 0.00% | – |
| Q2 2020 | $1,189,000 | – | 94,743 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |